In a meta-analysis on cancer prognosis, high CXCL12 expression was associated with reduced absolute survival in patients with esophagogastric, pancreatic or lung cancer whereas the opposite was true in breast cancer patients. This evidence concerns the gene CXCL12 and cancer.